UNSPSC 51201571: Blinatumomab

A bispecific CD19-directed CD3 T-cell engager indicated for the treatment of Philadelphia chromosome-negative relapsed or refractory Bcell precursor acute lymphoblastic leukemia.

UNSPSC 51201571 Blinatumomab is a Commodity code assigned to a biopharmaceutical product, yet recent state and local contract opportunities tagged under this code show no procurement activity for the named pharmaceutical itself. The three recent opportunities on file involve a District Attorney's office dog, athletic training services for fire and police departments, and medical aid supplies for fire rescue — none of which relate to blinatumomab or oncology therapeutics. The code designation appears misaligned with the actual solicitations, suggesting either a data-entry error in the state and local opportunity tagging or that this code is dormant for state and local purchasing.

Geographic activity across the recent records spans Oregon, Arizona, and Florida. Washington County, Oregon issued an RFP for a District Attorney's Office Dog due August 14, 2026; the City of Tucson issued an RFP for Athletic Training Services for fire and police departments due June 9, 2026; and the City of Tampa issued an ITB for Medical Aid Supplies due April 9, 2025 (note: this date appears to be a past entry relative to the posting date). No recent state and local opportunities in the database show procurement of blinatumomab or related immunotherapy drugs under this code. Business development professionals should verify the correct UNSPSC classification for pharmaceutical opportunities or confirm whether state and local governments are procuring this product through alternate codes or cooperative purchasing agreements.